Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...

Sartorius Stedim Biotech SA / Key word (s): Dividend Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting 07-Feb-2025 ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Richard Wang has been named as chief executive of the joint venture, named Fosun Kite Biotechnology. Wang has extensive experience in the industry including roles at Procter & Gamble ...

Gilead pounced to buy cell therapy company Kite in August last year for just under $12 billion, shortly before the biotech firm gained approval for its CAR-T cancer therapy Yescarta. Now Gilead is ...

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Cilta-cel enables sustained MRD negativity in patients with previously treated MM, according to results from the CARTITUDE-4 trial.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Biotech giant Gilead Sciences, Inc.’s (NASDAQ:GILD) $11.8 billion deal to buy CAR-T cancer therapy designer, Kite Pharma, Inc. (NASDAQ:KITE) has made two other leading... Abeona Therapeutics Inc ...

In our weekly column, Quick Bites, we round up the latest developments in the alt-protein and sustainable food industry.

According to the report, 53 PSUs recorded a total profit of ₹1,912.97 crore, compared to 61 profit-making entities in the ...